[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-369451-105":59,"doc-detail-369451-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-cost-effectiveness-of-genomic-medicine-in-cancer-control-a-systematic-literature-review","The Cost Effectiveness of Genomic Medicine in Cancer Control - A Systematic Literature Review","","Genomic medicine provides a new opportunity to improve cancer outcomes through prevention, early detection, and precision therapy, yet translation into routine cancer care has progressed slowly. This systematic review synthesizes published evidence on the cost effectiveness of genomic medicine in cancer control to support efforts to accelerate access to cost-effective human genomics applications. The protocol was registered with PROSPERO and conducted using PRISMA methods across four databases.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-cost-effectiveness-of-genomic-medicine-in-cancer-control-a-systematic-literature-review/369451/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-cost-effectiveness-of-genomic-medicine-in-cancer-control-a-systematic-literature-review/369451.png","ImageObject",300,407,{"name":92,"@type":93},"Kyle","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What was the objective of the systematic review?","Question",{"text":112,"@type":113},"To identify and synthesize published evidence on the cost effectiveness of genomic medicine in cancer control, supporting efforts to accelerate access to cost-effective human genomics applications.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How was the review conducted and what sources were searched?",{"text":117,"@type":113},"The protocol was registered with PROSPERO and the review followed PRISMA guidelines. Searches were run in MEDLINE, Embase, CINAHL, and EconLit, including English full economic evaluations published after 2018.",{"name":119,"@type":110,"acceptedAnswer":120},"Which cancer areas showed the strongest cost-effectiveness evidence?",{"text":121,"@type":113},"Evidence converged for prevention and early detection of breast and ovarian cancers and for colorectal and endometrial cancers. For treatment, genomic testing guiding therapy was highly likely to be cost effective for breast and blood cancers.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},369451,1790660233,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},3985741905716,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","Applied Health Economics and Health Policy (2025) 23:359–393  \n[https://doi.org/10.1007/s40258-025-00949-w](https://doi.org/10.1007/s40258-025-00949-w)  \nThe Cost Effectiveness of Genomic Medicine in Cancer Control: A Systematic Literature Review  \nMackenzie Bourke1 · Aideen McInerney‑Leo2 · Julia Steinberg3 · Tiffany Boughtwood4 · Vivienne Milch5,6 · Anna Laura Ross7 · Elena Ambrosino7 · Kim Dalziel8 · Fanny Franchini9,10 · Li Huang8 · Riccarda Peters1 · Francisco Santos Gonzalez1 · Ilias Goranitis1,4  \nAccepted: 19 January 2025 / Published online: 29 March 2025 © World Health Organization, and The Authors 2025  \nAbstract  \nBackground and Objective Genomic medicine offers an unprecedented opportunity to improve cancer outcomes through prevention, early detection and precision therapy. Health policy makers worldwide are developing strategies to embed genomic medicine in routine cancer care. Successful translation of genomic medicine, however, remains slow. This systematic review aims to identify and synthesise published evidence on the cost effectiveness of genomic medicine in cancer control. The insights could support efforts to accelerate access to cost-effective applications of human genomics.  \nMethods The study protocol was registered with PROSPERO (CRD42024480842), and the review was conducted in line with Preferred Reporting Items for Systematic Reviews and Meta Analyses (PRISMA) Guidelines. The search was run in four databases: MEDLINE, Embase, CINAHL and EconLit. Full economic evaluations of genomic technologies at any stage of cancer care, and published after 2018 and in English, were included for data extraction.  \nResults The review identified 137 articles that met the inclusion criteria. Most economic evaluations focused on the prevention and early detection stage (n = 44; 32%), the treatment stage (n = 36; 26%), and managing relapsed, refractory or progressive disease (n = 51, 37%) . Convergent cost-effectiveness evidence was identified for the prevention and early detection of breast and ovarian cancer, and for colorectal and endometrial cancers. For cancer treatment, the use of genomic testing for guiding therapy was highly likely to be cost effective for breast and blood cancers. Studies reported that genomic medicine was cost effective for advanced and metastatic non-small cell lung cancer. There was insufficient or mixed evidence regarding the cost effectiveness of genomic medicine in the management of other cancers.  \nConclusions This review mapped out the cost-effectiveness evidence of genomic medicine across the cancer care continuum. Gaps in the literature mean that potentially cost-effective uses of genomic medicine in cancer control, for example rare cancers or cancers of unknown primary, may be being overlooked. Evidence on the value of information and budget impact are critical, and advancements in methods to include distributional effects, system capacity and consumer preferences will be valuable. Expanding the current cost-effectiveness evidence base is essential to enable the sustainable and equitable translation of genomic medicine.  \n1 Introduction  \nCancer is a leading cause of mortality globally, with an estimated 10 million deaths annually around the world, 65% of which take place in low-and middle-income countries [1, 2] . Cancer mortality is expected to increase to 35 million by 2050 [3] . Genetic variations in human genomes, such as hereditary or environmental factors, determine cancer susceptibility and development and may influence therapeutic  \noutcomes. Genomic medicine (GM) uses genomic information to understand the risk of developing cancer and enable targeted treatment decisions [4, 5], providing an unprecedented opportunity in cancer control through prevention, early detection and precision therapy [6, 7] . Governments worldwide are developing strategies to embed genomics across the cancer care continuum [8, 9], and the World Health Organization has acknowledged the critical role o","cbCaiuML6bNXYz6c","https://ap.wps.com/l/cbCaiuML6bNXYz6c","pdf",1289474,35,"English","# Abstract\n## Background and Objective\n## Methods\n## Results\n## Conclusions\n# Introduction\n## Key Points for Decision Makers","[{\"question\":\"What was the objective of the systematic review?\",\"answer\":\"To identify and synthesize published evidence on the cost effectiveness of genomic medicine in cancer control, supporting efforts to accelerate access to cost-effective human genomics applications.\"},{\"question\":\"How was the review conducted and what sources were searched?\",\"answer\":\"The protocol was registered with PROSPERO and the review followed PRISMA guidelines. Searches were run in MEDLINE, Embase, CINAHL, and EconLit, including English full economic evaluations published after 2018.\"},{\"question\":\"Which cancer areas showed the strongest cost-effectiveness evidence?\",\"answer\":\"Evidence converged for prevention and early detection of breast and ovarian cancers and for colorectal and endometrial cancers. For treatment, genomic testing guiding therapy was highly likely to be cost effective for breast and blood cancers.\"}]","The Cost Effectiveness of Genomic Medicine in Cancer Control - A Systematic Literature Review | PDF",1790182756,88,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fa57c3b0e011763ff449f8cb13e1c94e.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/24d00040e5083d6ba78405e31dfafd5b.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/dc7d2dd789eb7ced5b738c007a8b300d.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ae45004a3eb0864f1707cfeafd084f00.webp",980,1301]